Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Switching Study in Schizophrenia (SWAT)
NCT00304616Phase 4Completed
- Sponsor
- Otsuka Holdings
- Start
- Oct 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole in schizophrenia and schizoaffective disorder (2 arms), sponsored by Otsuka Holdings. Primary endpoint: Clinical Global Impressions - Improvement at 26 weeks. Started Oct 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00304616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304616.